发明授权
- 专利标题: 2,3,6-Trisubstituted-4-pyrimidone derivatives
- 专利标题(中): 2,3,6-三取代-4-嘧啶酮衍生物
-
申请号: US10550299申请日: 2004-03-26
-
公开(公告)号: US07504411B2公开(公告)日: 2009-03-17
- 发明人: Kazutoshi Watanabe , Fumiaki Uehara , Shinsuke Hiki , Satoshi Yokoshima , Yoshihiro Usui , Masahiro Okuyama , Aya Shoda , Keiichi Aritomo , Toshiyuki Kohara , Kenji Fukunaga
- 申请人: Kazutoshi Watanabe , Fumiaki Uehara , Shinsuke Hiki , Satoshi Yokoshima , Yoshihiro Usui , Masahiro Okuyama , Aya Shoda , Keiichi Aritomo , Toshiyuki Kohara , Kenji Fukunaga
- 申请人地址: JP Osaka FR Paris
- 专利权人: Mitsubishi Tanabe Pharma Corporation,Sanofi-Aventis
- 当前专利权人: Mitsubishi Tanabe Pharma Corporation,Sanofi-Aventis
- 当前专利权人地址: JP Osaka FR Paris
- 代理机构: Greenblum & Bernstein, P.L.C.
- 优先权: JP2003-126021 20030326; JP2003-126022 20030326
- 国际申请: PCT/JP2004/004320 WO 20040326
- 国际公布: WO2004/085408 WO 20041007
- 主分类号: C07D401/14
- IPC分类号: C07D401/14 ; C07D403/14 ; A61K31/496 ; A61K31/506 ; A61P3/10 ; A61P25/28
摘要:
A pyrimidone derivative having tau protein kinase 1 inhibitory activity which is represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof; useful for prventive and/or therapeutic treatment of diseass such as neurodegenerative diseases (e.g. Alzheimer disease); wherein Q represents CH or nitrogen atom; R represents a C1-C12 alkyl group; the ring of Formula (I): represents piperazine ring or piperidine ring; each X independently represents a C1-C8 alkyl group, an optionally partially hydrogenated C6-C10 aryl ring, an indan ring or the like; m represents an integer of 1 to 3; each independently represents a halogen atom, a hydroxy group, a cyano group, a C1-C6 alkyl group or the like; n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C2-C6 alkylene group.
公开/授权文献
- US20060252768A1 2,3,6-Trisubstituted-4-pyrimidone derivatives 公开/授权日:2006-11-09
信息查询